


Gobierno de Chile

Effectiveness of the inactivated CoronaVac vaccine against SARS-CoV-2 in Chile

Preliminary report


Presented by: Dr. Rafael Araos
Advisor to the Undersecretariat of Public Health
Researcher Universidad del Desarrollo

STATUS OF SARS-COV-2 IN CHILE




STATUS OF SARS-COV-2 IN CHILE

Evolution incidence rate per every 100 thousand people By age group



STATUS OF SARS-COV-2 IN CHILE



PROGRESS OF THE SARS-COV-2 IMMUNIZATION SCHEDULE



SARS-CoV-2 Vaccination Campaign. Country wide

(Number of vaccines administered)

Number of administered doses 12,726,959

People vaccinated with 1 dose 7,600,908

People vaccinated with 2 doses 5,126,051


Target population to be vaccinated 15,200,840

Vaccination coverage (people with 1 and 2 doses) 33.7%

Region	% of people with 1 and 2 doses	
Total	33.7%	
Región de Aisén del Gral. C. Ibáñez del Campo	39.1%	
Región de Antofagasta	27.2%	
Región de Arica y Parinacota	29.7%	
Región de Atacama	30.7%	
Región de Coquimbo	32.7%	
Región de La Araucanía	37.2%	
Región de Los Lagos	35.6%	
Región de Los Ríos	38.2%	
Región de Magallanes y la Antártica Chilena	44.7%	
Región de Ñuble	42.4%	
Región de Tarapacá	27.7%	
Región de Valparaíso	37.5%	
Región del Biobío	37.7%	
Región del Libertador B. O'Higgins	37.0%	
Región del Maule	36.3%	
Región Metropolitana de Santiago	30.79	


AVANCE DEL PROGRAMA DE INMUNIZACIÓN CONTRA SARS-COV-2

33.7% of the target population has been fully vaccinated



CASES IN TIME


Evolution of new cases (2021) Indexed to 100 by 02/03/2021 for each age group



HOSPITAL ADMISSIONS IN TIME

Evolution of new admissions to any type of bed (2021)


Indexed to 100 by 02/03/2021 for each age group



ICU ADMISSIONS IN TIME

Evolution of new admissions to ICU (2021)


Indexed to 100 by 02/03/2021 for each age group



DEATHS DUE TO COVID-19 IN TIME



Indexed to 100 by 02/03/2021 for each age group



PRELIMINARY EFFECTIVENESS OF CORONAVAC

- > vCOVID cohort Chile ~10,500,000 individuals (>16 years) under the National Health Fund (FONASA)
- > Compares outcomes between people vaccinated by CoronaVac® or unvaccinated (02/02/2021 04/01/2021) adjusted by age, gender, region of residence, income level, and nationality
 - Outcomes
 - Covid-19 symptomatic (cases confirmed by RT-PCR or antigen test for SARS-CoV-2)
 - Hospital admissions
 - ICU admissions
 - Deaths due to Covid-19 (U07.1)
- Groups to be compared
 - Unvaccinated
 - Partially vaccinated (≥14 days after the first dose)
 - Fully vaccinated (≥ 14 days after the second dose)
 - The period between days 0 13 after the first or second doses were not considered ("unknown" state of immunity)

RESULTS

EFFECTIVENESS OF CORONAVAC® 14 DAYS AFTER THE SECOND DOSE

67% (65% - 69%)

Effectiveness to prevent

Symptomatic Covid-19

85% (83% - 87%)

Effectiveness to prevent Hospital admission

89% (84% - 92%)

Effectiveness to prevent ICU admission

80% (73% - 86%)

Effectiveness to prevent **Death**

EFFECTIVNESS OF CORONAVAC (1 and 2 doses)

Vaccination status	Effectiveness (IC 95%)	
	100% x 1 - HR	
COVID 19		
Unvaccinated		
Partially vaccinated group	16.13	
≥ 14 days after 1st dose	(14.30; 17:92)	
Fully vaccinated group	66.96	
≥ 14 days after 2nd dose	(65.28; 68.55)	
Hospital admissions		
Unvaccinated		
Partially vaccinated group	36.65	
> 14 days after 1st dose	(32.13; 38.99)	
Fully vaccinated group	84.84	
≥ 14 days after 2nd dose	(82.52; 86.85)	
ICU admissions		
Unvaccinated		
Partially vaccinated group	42.70	
≥ 14 days after 1st dose	(37.08; 42.82)	
Fully vaccinated group	88.55	
≥ 14 days after 2nd dose	(84.46; 91.56)	
Deaths due to COVID 1	9	
Unvaccinated		
Partially vaccinated group	40.23	
≥ 14 days after 1st dose	(32.63; 46.97)	
Fully vaccinated group	80.44	
≥ 14 days after 2nd dose	(73.16; 85.75)	


WHAT SHOULD WE UNDERSTAND BY EFFECTIVENESS?

It is the protection provided by a vaccine under real-life conditions


What do results tell us?

- Effectiveness of 67% to prevent Covid-19
 - Out of 100 people who could have had Covid-19, there would have only been 33 cases, if we are all vaccinated.
- Effectiveness of 80% to prevent deaths due to Covid-19
 - > Out of 100 people who could have died from Covid-19, 20 would actually do, if we are all vaccinated.


SYMPTOMATIC CASES




SYMPTOMATIC CASES




HOSPITAL ADMISSIONS




HOSPITAL ADMISSIONS




ICU ADMISSION CASES




ICU ADMISSION CASES



CONFIRMED DEATHS



CONFIRMED DEATHS



CONCLUSIONS

- > In a scenario of high epidemic activity), the vaccine studied protects susceptible groups (the elderly and people with comorbidities) against symptomatic SARS-CoV-2 infection, as well as against the most severe forms of the disease.
- > Since we do not have 100%-effective vaccines, it is essential that we ALL get.
- > No se deben descuidar las medidas de salud pública adicionales a la inmunización.
 - Hygiene and personal care, mobility restrictions

This is a preliminary report and it will be updated on a monthly basis

ACKNOWLEDGEMENTS

Team at the Ministry of Health

- National Immunization Program (PNI)
- Health Planning Division, Epidemiology Department, Health Statistics and Information Department
- National Health Fund (FONASA)
- Public Helth Institute (ISP)
- Primary Healthcare Division (DIVAP)

Academic Team

- School of Medicine Clínica Alemana Universidad del Desarrollo
- Pontificia Universidad Católica de Chile
- Covid-19 Advisory Council



PLAN NACIONAL DE VACUNACIÓN COVID-19

#Sigamos**Cuidándonos**



Ministerio de Salud

Gobierno de Chile



Ministerio de Salud

Gobierno de Chile



Ministerio de Salud

Gobierno de Chile